

## FLOVENT HFA - (0.044,0.11,0.22 mg/INH;Aerosol,Metered,Inhalation)

|                              |   |                             |                     |
|------------------------------|---|-----------------------------|---------------------|
| <b>Generic Name</b>          | FLUTICASONE PROPIONATE                              | <b>Innovator</b>            | GlaxoSmithkline     |
| <b>Dosage</b>                | 0.044,0.11,0.22 mg/INH;Aerosol,Metered,Inhalation   | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5   | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | More Than 5   | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | None  | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | Used to treat asthma in patients 4 years and older. |                             |                     |
| <b>Complexities</b>          | Yes   |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## FLOVENT HFA - (0.22 mcg/inh ; Inhalation Aerosol)

|                              |   |                             |                     |
|------------------------------|---|-----------------------------|---------------------|
| <b>Generic Name</b>          | FLUTICASONE PROPIONATE  | <b>Innovator</b>            | GlaxoSmithkline     |
| <b>Dosage</b>                | 0.22 mcg/inh ; Inhalation Aerosol   | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | None  | <b>Known Para IV Filers</b> | None                |
| <b>Other ANDA developers</b> | More Than 5   | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | None  | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | FLOVENT HFA Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in adolescent and adult patients 12 years of age and older. It is also indicated for patients requiring oral corticosteroid therapy for asthma. Many of these patients may be able to reduce or eliminate their requirement for oral corticosteroids over time. |                             |                     |
| <b>Complexities</b>          | Yes   |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.